TIRAT CARMEL, ISRAEL--(Aug. 31, 2010) - D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMDC) ("D. Medical"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced financial results for the three and six months ended June 30, 2010. The unaudited selected consolidated financial statements presented below were prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). A convenience U.S. dollar translation of NIS amounts is provided using the rate of NIS 3.875 to US$1.00, the representative rate of exchange as of June 30, 2010 as published by the Bank of Israel.
Second Quarter Highlights:
- Second quarter sales increased 33% on a sequential basis to NIS 721 thousand (US$ 186 thousand), as compared to NIS 543 thousand (US$ 140 thousand) for the first quarter of 2010. - Second quarter cost of sales increased 10% on a sequential basis to NIS 1,431 thousand (US$ 369 thousand), as compared to NIS 1,298 thousand (US$ 1,554 thousand) for the first quarter of 2010. - Operating loss for the second quarter decreased 6% on a sequential basis to NIS 6,022 thousand (US$ 1,544 thousand), as compared to NIS 6,399 thousand (US$ 1,651 thousand) for the first quarter of 2010.
D. Medical commenced sales and marketing operations in late 2009. Sales for the three and six months ended June 30, 2010 amounted to NIS 721 thousand (US$ 186 thousand) and NIS 1,264 thousand (US$ 326 thousand), respectively. Cost of sales for the three and six months ended June 30, 2010 amounted to NIS 1,431 thousand (US$ 369 thousand) and NIS 2,729 thousand (US$ 704 thousand), respectively. D. Medical had no sales and costs of sales for the periods ended June 30, 2009, during which period it was still focusing solely on its research and development operations.
D. Medical's comprehensive loss for the three months ended June 30, 2010 amounted to NIS 6,314 thousand (US$ 1,629 thousand), or NIS 1.03 (U.S. $0.26) per share, as compared to NIS 9,270 thousand (US$ 2,392 thousand), or NIS 2.02 (US$ 0.52) per share, for the three months ended June 30, 2009. D. Medical's loss for the six months ended June 30, 2010 amounted to NIS 21,203 thousand (US$ 5,471 thousand), or NIS 3.64 (US$ 0.94) per share, as compared to NIS 12,100 thousand (US$ 3,123 thousand), or NIS 2.59 (US$ 0.67) per share, for the six months ended June 30, 2009. The loss for the first six months of 2010 reflects registration costs of NIS 6,049 thousand (US$ 1,561 thousand) and fair value losses on warrants at fair value through profit or loss of NIS 2,469 thousand (US$ 637 thousand) as a component of financial costs, all incurred during the first three months of 2010. Therefore, on a sequential basis, comprehensive loss for the second quarter decreased 58%.
"These financial results reflect our recent transition from an R&D company into a commercially viable company and, in turn, the very early stages of commercialization of our Adi insulin pump and our universal infusion sets in select European countries," said Efri Argaman, D. Medical's Chief Executive Officer. "As we move forward to mass production with the help of our new manufacturing partner, UPG, we expect to expand our manufacturing volumes and reduce our cost of sales. This will allow us to more fully capitalize on the cost-effectiveness of our unique spring-based design as we prepare to launch product sales in our five initial target markets - Mexico and the BRIC countries of Brazil, Russia, India and China - commencing in 2011."
As of June 30, 2010, D. Medical had cash and cash equivalents of NIS 30,383 thousand (US$ 7,841 thousand), as compared to NIS 24,388 thousand (US$ 6,294 thousand) as of December 31 2009. The increase was mainly attributable to proceeds from the exercise of warrants less the cash used in operating activities.
Recent Highlights:
- In August 2010, D. Medical consummated its initial public offering in the United States of 1,500,906 of its ordinary shares at a price per shares of US$7.00, thereby raising gross proceeds of NIS 40,712 thousand (US$ 10,506 thousand) and significantly increasing the cash resources available to fund its commercialization efforts. - In August 2010, D. Medical entered into a definitive manufacturing and supply agreement with UPG (Suzhou) EPZ Co. Ltd.
Conference Call
D. Medical will host a conference call to discuss these results today, August 31, at 8:30 a.m. (Eastern Standard Time). Those wishing to access the live conference call by telephone should dial 877-312-5445 (within the United States) or 253-237-1128 (outside of the United States) several minutes prior to the beginning of the call. The call will also be webcast live and archived for 30 days on the company's website at http://www.dmedicalindustries.com under the "Events" tab in the Investors section.
About D. Medical
D. Medical is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. D. Medical has also developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch. For more information, visit http://www.dmedicalindustries.com.
Forward-Looking Statements
This press release contains forward-looking statements (as defined by the Israeli Securities Law, 1968, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties. These statements include, forecasts, goals, uncertainties and assumptions and relate, inter alia, to D. Medical's future expectations in connection with its level of sales and cost of sales, manufacturing volumes, the cost-effectiveness of its spring-based design and timing of markets penetration. The forward-looking statements are based on D. Medical's current expectations and beliefs which are based on, among other things, its analysis of publicly available information and market research reports. All forward-looking statements are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact of general economic conditions, competitive products, product demand, the performance of D. Medical's contract manufacturer and distributors, regulatory trends and approvals and healthcare reform legislation. If one or more of these risks and/or uncertainties materialize, or if the underlying assumptions prove to be incorrect, D. Medical's actual results, performance or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements or results which are based upon such assumptions. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or of any of them will transpire or occur, what impact it will have on D. Medical's results of operations or financial condition. D. Medicals does not undertake to update any forward-looking statements.
| D MEDICAL INDUSTRIES LTD. |
| CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
| NIS in thousands |
| Convenience translation into US$ (in thousands) | |||||||||
| June 30, | December 31, | June 30, | |||||||
| 2010 | 2009 | 2010 | |||||||
| (Unaudited) | (Audited) | (Unaudited) | |||||||
| Assets | |||||||||
| CURRENT ASSETS: | |||||||||
| Cash and cash equivalents | 30,383 | 24,388 | 7,841 | ||||||
| Short term deposits | - | 208 | - | ||||||
| Trade accounts receivable | 1,119 | 103 | 289 | ||||||
| Other | 1,596 | 1,097 | 412 | ||||||
| Inventory | 1,349 | 499 | 348 | ||||||
| Total current assets | 34,447 | 26,295 | 8,890 | ||||||
| NON-CURRENT ASSETS : | |||||||||
| Property and equipment, net | 2,252 | 2,103 | 582 | ||||||
| Intangible assets, net | 14,477 | 14,482 | 3,736 | ||||||
| Long-term deposits and loans | 176 | 285 | 45 | ||||||
| Deferred charges | 1,949 | - | 503 | ||||||
| Total non-current assets | 18,854 | 16,870 | 4,866 | ||||||
| Total assets | 53,301 | 43,165 | 13,756 | ||||||
| Liabilities and equity | |||||||||
| CURRENT LIABILITIES: | |||||||||
| Trade and other payables: | |||||||||
| Trade accounts payable | 1,653 | 1,165 | 427 | ||||||
| Other | 2,446 | 2,695 | 631 | ||||||
| Total current liabilities | 4,099 | 3,860 | 1,058 | ||||||
| NON-CURRENT LIABILITIES: | |||||||||
| Warrants | - | 2,606 | - | ||||||
| Provision for royalties to the Israeli Office of Chief Scientist | 4,753 | 4,048 | 1,227 | ||||||
| Liability to minority interest | 3,328 | 3,085 | 859 | ||||||
| Liability for severance pay - net | 71 | 233 | 18 | ||||||
| Total non-current liabilities | 8,152 | 9,972 | 2,104 | ||||||
| Total liabilities | 12,251 | 13,832 | 3,162 | ||||||
| EQUITY: | |||||||||
| Equity attributable to owners of the parent: | |||||||||
| Share capital - issued and outstanding - | |||||||||
| December 31, 2009 – 5,384,342 shares June 30, 2010 - 6,124,617 shares | |||||||||
| Ordinary shares | 2,020 | 1,783 | 521 | ||||||
| Share premium and other reserves | 196,395 | 167,355 | 50,683 | ||||||
| Warrants and equity portion of convertible debt | 3,048 | 3,048 | 787 | ||||||
| Accumulated losses | (163,429 | ) | (143,442 | ) | (42,175 | ) | |||
| 38,034 | 28,744 | 9,816 | |||||||
| MINORITY INTEREST | 3,016 | 589 | 778 | ||||||
| Total equity | 41,050 | 29,333 | 10,594 | ||||||
| Total liabilities and equity | 53,301 | 43,165 | 13,756 | ||||||
| D MEDICAL INDUSTRIES LTD. |
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS |
| NIS in thousands except per share data |
| Convenience translation into US$ (in thousands) | ||||||||||||||||
| Three months ended June 30 | Six months ended June 30 | Year ended December 31, | Three months ended June 30 | Six months ended June 30 | ||||||||||||
| 2010 | 2009 | 2010 | 2009 | 2009 | 2010 | 2010 | ||||||||||
| (Unaudited) | (Audited) | (Unaudited) | ||||||||||||||
| CONTINUING OPERATIONS: | ||||||||||||||||
| Sales | 721 | - | 1,264 | - | 368 | 186 | 326 | |||||||||
| Cost of sales | 1,431 | - | 2,729 | - | 657 | 369 | 704 | |||||||||
| 710 | - | 1,465 | - | 289 | 183 | 378 | ||||||||||
| Research and development expenses - net | 2,058 | 3,137 | 4,310 | 6,193 | 13,193 | 531 | 1,112 | |||||||||
| Selling and marketing expenses | 738 | - | 1,322 | - | 698 | 190 | 341 | |||||||||
| General and administrative expenses | 2,645 | 1,339 | 5,222 | 2,155 | 5,563 | 683 | 1,348 | |||||||||
| Other (income) expenses - net | (129 | ) | (196 | ) | 102 | (126 | ) | (714 | ) | (33 | ) | 26 | ||||
| Operating loss | 6,022 | 4,280 | 12,421 | 8,222 | 19,029 | 1,554 | 3,205 | |||||||||
| Registration costs | - | - | 6,049 | - | - | - | 1,561 | |||||||||
| Finance income | (122 | ) | (16 | ) | (151 | ) | (870 | ) | (243 | ) | (31 | ) | (39 | ) | ||
| Fair value losses (gains) on warrants at fair value through profit or loss | - | 4,455 | 2,469 | 4,065 | (244 | ) | - | 637 | ||||||||
| Finance costs | 414 | 551 | 415 | 683 | 473 | 106 | 107 | |||||||||
| Finance (income) costs - net | 292 | 4,990 | 2,733 | 3,878 | (14 | ) | 75 | 705 | ||||||||
| LOSS AND TOTAL COMPREHENSIVE LOSS FOR THE PERIOD | 6,314 | 9,270 | 21,203 | 12,100 | 19,015 | 1,629 | 5,471 | |||||||||
| ATTRIBUTABLE TO: | ||||||||||||||||
| Owners of the parent | 5,644 | 9,175 | 19,989 | 11,670 | 18,435 | 1,457 | 5,158 | |||||||||
| Minority interest | 670 | 95 | 1,214 | 430 | 580 | 172 | 313 | |||||||||
| 6,314 | 9,270 | 21,203 | 12,100 | 19,015 | 1,629 | 5,471 | ||||||||||
| LOSS PER SHARE ATTRIBUTABLE | ||||||||||||||||
| TO THE EQUITY HOLDERS OF THE COMPANY: | ||||||||||||||||
| Basic and diluted | 1.03 | 2.02 | 3.64 | 2.59 | 3.89 | 0.26 | 0.94 | |||||||||